fashion -WSS

fashion

author：focus 2025-09-30 06:09:19 - browse：1

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： $1 billion proposal to grow Boston, Massachusetts biotech

WSS

Readout Newsletter: Merck, J&J, and long Covid

Why doctors need education on FDA device approval process

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

$1 billion proposal to grow Boston, Massachusetts biotech

Stem cell biologist probes earliest stages of human development

FDA clears AI tool for detecting skin cancer

knowledge

fashion

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Sports medicine is finally prioritizing gender equality

Pregnant women don't need prenatal multivitamins, study concludes

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare Advantage today, explained in one chart

Apple is now the first public company to be valued at $3 trillion

My yearlong odyssey to get my son’s ADHD medication covered

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The tragedy of Johnson & Johnson’s Covid vaccine

entertainment

Eli Lilly, Pfizer, and others want in on the online prescription market

Families look for replacement for GSK asthma drug Flovent

Parkinson’s finding may lead to tests and, someday, treatments

Ancient Greek ideas underpin modern concepts of pregnancy

Research misconduct: Proposed new rules face resistance

EU regulator recommends expanding Mounjaro approval to obesity

Wikipedia

focus

hotspot

focus